Monographie - Scopolamine N-butyl bromide

Laatste update :
08/05/2024

Scopolamine N-butyl bromide

Molecuulstructuur

Merknamen in verschillende landen

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Buscapina	Spanje
Buscolysin	Polen
Buscopan	Australië, België, Brazilië, Canada, Duitsland, Egypte, Finland, IJsland, Luxemburg, Nederland, Nieuw Zeeland, Noorwegen, Oostenrijk, Portugal, Tunisie, Turkije, Verenigde Arabische Emiraten, Zweden, Zwitserland
Butilbromuro de hioscina	Argentinië, Colombia
Cifespasmo	Argentinië
Colobolina	Argentinië
Dolopina	Ecuador
Escopolamina N butyl bromuro	Chili
Hiocin	Venezuela
Hioscina	Argentinië, Colombia, Peru
Hioscina butil bromuro	Colombia, Peru
Hyocidic	Iran
Hyoscine	Australië
Hyoscine hydrobromide	Canada
Hyotex	Iran
Pasmodina Drawer	Argentinië
Rupe N	Argentinië
Scoburen	Frankrijk
Selpirans	Venezuela
Spasmopan	Tunisie
Xemol	Turkije

Literatuur : Scopolamine N-butyl bromide

	Type	Publicatie
1230	Artikel	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Artikel	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Artikel	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1757	Artikel	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1847	Artikel	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966	Artikel	Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer 2005 ; 13, 4: 239-245.
1970	Artikel	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Artikel	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
2055	Artikel	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2125	Artikel	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2176	Artikel	Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007 ; 15: 57-62.
2900	Artikel	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Artikel	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019

Mentions Légales